查看购物车
  • Traditional Chinese
  • English
2021-2031年欧洲胃肠药物市场报告（范围、细分、动态和竞争分析）
市场调查报告书
商品编码
1819736

2021-2031年欧洲胃肠药物市场报告（范围、细分、动态和竞争分析）

Europe Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 165 Pages | 订单完成后即时交付

价格

欧洲胃肠药物市场预计将大幅成长，到 2031 年将达到约 342.9935 亿美元，高于 2023 年的 196.5029 亿美元。这一成长代表着 2023 年至 2031 年的年复合成长率(CAGR) 为 7.2%。

执行摘要和市场分析

欧洲胃肠道药物市场主要分为几个主要区域，包括德国、英国、法国、义大利、西班牙和欧洲其他地区。该市场的预期成长主要受发炎性肠道疾病 (IBD) 和肠躁症 (IBS) 等胃肠道疾病盛行率上升的推动。此外，研发活动也显着增加，促进了针对各种胃肠道疾病的先进治疗方案的研发。

市场区隔分析

对欧洲胃肠药物市场的分析揭示了几个重要的部分，包括药物类别、应用、给药途径和配销通路。

1. 药品类别：市场分为生物製剂、止泻药和泻药、酸中和剂、抗发炎药、止吐药和止吐药等。 2023年，生物製剂占据了最大的市场。

2. 应用：市场根据应用细分，例如肠躁症、发炎性溃疡性结肠炎、克隆氏症、胃肠炎、乳糜泻等。肠躁症是2023年市场的最大贡献者。

3. 给药途径：市场分为口服和非肠道给药途径。口服给药在2023年占据了更大的份额，这反映了患者的偏好和易用性。

4.配销通路：分销管道包括医院药房、零售药房和线上药房。 2023年，医院药房占据了最大的市场份额，这表明医疗机构在配药方面存在很大的依赖性。

市场展望

胃肠道疾病涵盖一系列影响胃肠道的疾病，包括灼热、发炎性肠道疾病 (IBD)、肠躁症 (IBS)、胃肠炎、胃食道逆流症 (GERD)、便秘和腹泻等常见问题。这些疾病是常见的慢性发炎性疾病，影响全球相当一部分人口。导致胃肠道疾病发生率上升的因素包括久坐不动的生活方式、饮食习惯的改变以及压力水平的增加。随着人口老化，这些疾病的负担预计将持续上升。

2023年7月发表的一项题为《胃食道逆流症》的最新研究强调，GERD是最常见的胃肠道疾病之一，影响约20%的人口。这种疾病不仅透过直接和间接成本造成巨大的经济负担，也严重影响个人的生活品质。

欧洲慢性消化系统疾病的发生率不断上升，而人口老化和生活方式因素（包括肥胖率上升和高酒精消费）进一步加剧了这一趋势。根据欧洲克隆氏症和溃疡性结肠炎协会联合会的数据，全球约有1,000万人患有发炎性肠道疾病（IBD）。英国克隆氏症和结肠炎协会2022年的研究表明，英国每123人中就有1人被诊断出患有克隆氏症或溃疡性结肠炎，总数约为50万人。

此外，近几十年来，肠躁症（IBS）的盛行率急剧上升。国际胃肠病基金会报告称，IBS是最常见的功能性胃肠病，影响全球10%至15%的人口。哥德堡大学的一项研究发现，全球每十个成年人中就有四个患有不同程度的功能性胃肠病，美国每年约有240万至350万人次因IBS就诊。胃肠疾病盛行率的上升推动了对有效治疗的需求，从而推动了胃肠药物市场的成长。

国家洞察

欧洲胃肠道药物市场进一步按国家/地区进行分析，其中德国在2023年占据市场份额的首位。由于胃肠道感染和疾病的发生率不断上升，德国市场尤其具有吸引力。根据《德国医学杂誌》（Deutsches Arzteblatt）2023年的一篇文章，发炎性肠道疾病（IBD）的盛行率正在迅速上升，影响了约0.7%的德国人口，约60万名患者。此外，胃肠道感染每年在德国约造成2,450万人次的门诊就诊。

各製药公司不断开发有效的治疗方案，加之易患胃肠道疾病的老年人口不断增长，预计将推动德国市场的成长。例如，2021年10月，Renexxion Ireland Ltd. 与 Dr. Falk Pharma GmbH 合作开发并商业化了用于治疗胃轻瘫的新型胃肠道促动力药那罗那必利 (Naronapride)。德国是欧洲最大的医药市场，2021年的产值达380.3亿美元，并在研发方面投入了大量资金，这进一步支持了该地区胃肠道药物市场的成长。

公司简介

欧洲胃肠药物市场的主要参与者包括赛诺菲公司、葛兰素史克公司、强生公司、博士伦健康公司、阿斯特捷利康公司、武田製药有限公司、艾伯维公司、拜耳公司和辉瑞公司。这些公司正在采用各种策略，包括扩张、产品创新和併购，以增强其市场占有率并为消费者提供创新解决方案。

目录

第一章：简介

第二章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：欧洲胃肠药物市场－主要市场动态

  • 市场驱动因素
    • 胃肠道疾病病例增加
    • 生物製剂的不断发展
  • 市场限制
    • 生物製剂成本高
    • 治疗严重溃疡性结肠炎或克隆氏症的生物製剂平均费用
  • 市场机会
    • 企业的策略倡议
  • 未来趋势
    • 加大对新药开发与人工智慧技术的研究投入
  • 驱动因素和限制因素的影响：

第五章：欧洲胃肠药物市场分析

  • 2021-2031年欧洲胃肠药物市场收入

第六章：欧洲胃肠药物市场分析－依药物类别

  • 生物製剂
  • 止泻药和泻药
  • 酸中和剂
  • 抗发炎药物
  • 止吐药和止噁心药
  • 其他的

第七章：欧洲胃肠药物市场分析-按应用

  • 急躁性肠症候群
  • 发炎性溃疡性结肠炎
  • 克罗恩病
  • 胃肠炎
  • 乳糜泻
  • 其他的

第八章：欧洲胃肠药物市场分析-按给药途径

  • 口服
  • 肠外

第九章：欧洲胃肠药物市场分析-按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：欧洲胃肠药物市场-国家分析

  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其余

第 11 章：产业格局

  • 概述
  • 胃肠药物市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 12 章：公司简介

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • Bayer AG
  • Pfizer Inc

第 13 章：附录

Product Code: TIPRE00016280

The European gastrointestinal drugs market is projected to grow significantly, reaching approximately USD 34,299.35 million by 2031, up from USD 19,650.29 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.2% from 2023 to 2031.

Executive Summary and Market Analysis

The market for gastrointestinal drugs in Europe is divided into several key regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The anticipated growth in this market is primarily driven by the increasing prevalence of gastrointestinal disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Additionally, there is a notable rise in research and development activities, which is fostering the creation of advanced therapeutic options for various gastrointestinal conditions.

Market Segmentation Analysis

The analysis of the European gastrointestinal drugs market reveals several important segments, including drug class, application, route of administration, and distribution channel.

1. Drug Class: The market is categorized into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share.

2. Application: The market is segmented based on applications such as irritable bowel syndrome, inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease, and others. The irritable bowel syndrome segment was the largest contributor to the market in 2023.

3. Route of Administration: The market is divided into oral and parenteral routes. The oral administration segment held a larger share in 2023, reflecting patient preferences and ease of use.

4. Distribution Channel: The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies represented the largest share of the market in 2023, indicating a strong reliance on healthcare facilities for dispensing these medications.

Market Outlook

Gastrointestinal diseases encompass a range of conditions affecting the gastrointestinal tract, including common issues like heartburn, IBD, IBS, gastroenteritis, gastroesophageal reflux disease (GERD), constipation, and diarrhea. These conditions are prevalent chronic inflammatory disorders that impact a significant portion of the global population. Factors contributing to the rise in gastrointestinal diseases include sedentary lifestyles, changing dietary habits, and increased stress levels. As the population ages, the burden of these diseases is expected to escalate.

A recent study titled "Gastroesophageal Reflux Disease," published in July 2023, highlighted that GERD is one of the most commonly diagnosed gastrointestinal conditions, affecting around 20% of the population. This condition not only imposes a substantial economic burden through direct and indirect costs but also significantly affects individuals' quality of life.

The increasing incidence of chronic digestive diseases in Europe is further exacerbated by an aging population and lifestyle factors, including rising obesity rates and high alcohol consumption. According to the European Federation of Crohn's & Ulcerative Colitis Associations, approximately 10 million individuals worldwide suffer from IBD. Research from Crohn's & Colitis UK in 2022 indicated that 1 in every 123 people in the UK is diagnosed with either Crohn's disease or ulcerative colitis, totaling around half a million individuals.

Moreover, the prevalence of IBS has surged in recent decades. The International Foundation for Gastrointestinal Disorders reports that IBS is the most common functional gastrointestinal disorder, affecting 10-15% of the global population. A study from the University of Gothenburg found that four out of ten adults worldwide experience varying degrees of functional gastrointestinal disorders, with the US seeing approximately 2.4 to 3.5 million hospital visits for IBS each year. This rising prevalence of gastrointestinal diseases is driving the demand for effective treatments, thereby propelling the growth of the gastrointestinal drugs market.

Country Insights

The European gastrointestinal drugs market is further analyzed by country, with Germany leading the market share in 2023. Germany's market is particularly attractive due to the increasing rates of gastrointestinal infections and disorders. According to a 2023 article from Deutsches Arzteblatt, the prevalence of IBD is rapidly rising, affecting about 0.7% of the German population, or approximately 600,000 patients. Additionally, gastrointestinal infections account for around 24.5 million outpatient visits annually in Germany.

The development of effective treatment options by various pharmaceutical companies, along with a growing elderly population susceptible to gastrointestinal issues, is expected to drive market growth in Germany. For instance, in October 2021, Renexxion Ireland Ltd. partnered with Dr. Falk Pharma GmbH to develop and commercialize Naronapride, a novel GI prokinetic for gastroparesis. Germany's status as Europe's largest pharmaceutical market, with a production volume of USD 38.03 billion in 2021 and a robust investment in research and development, further supports the growth of the gastrointestinal drugs market in the region.

Company Profiles

Key players in the European gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Gastrointestinal Drugs Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Cases of Gastrointestinal Diseases
    • 4.1.2 Increasing Development of Biologics
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
    • 4.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
  • 4.3 Market Opportunities
    • 4.3.1 Strategic Initiatives by Companies
  • 4.4 Future Trends
    • 4.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
  • 4.5 Impact of Drivers and Restraints:

5. Gastrointestinal Drugs Market - Europe Analysis

  • 5.1 Europe Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

6. Europe Gastrointestinal Drugs Market Analysis - by Drug Class

  • 6.1 Biologics
    • 6.1.1 Overview
    • 6.1.2 Biologics: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Antidiarrheal and Laxatives
    • 6.2.1 Overview
    • 6.2.2 Antidiarrheal and Laxatives: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Acid Neutralizers
    • 6.3.1 Overview
    • 6.3.2 Acid Neutralizers: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Anti-inflammatory Drugs
    • 6.4.1 Overview
    • 6.4.2 Anti-inflammatory Drugs: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Antiemetic and Antinauseants
    • 6.5.1 Overview
    • 6.5.2 Antiemetic and Antinauseants: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Gastrointestinal Drugs Market Analysis - by Application

  • 7.1 Irritable Bowel Syndrome
    • 7.1.1 Overview
    • 7.1.2 Irritable Bowel Syndrome: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Inflammatory Ulcerative Colitis
    • 7.2.1 Overview
    • 7.2.2 Inflammatory Ulcerative Colitis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Crohn's Disease
    • 7.3.1 Overview
    • 7.3.2 Crohn's Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Gastroenteritis
    • 7.4.1 Overview
    • 7.4.2 Gastroenteritis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Celiac Disease
    • 7.5.1 Overview
    • 7.5.2 Celiac Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Gastrointestinal Drugs Market Analysis - by Route Of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Parenteral
    • 8.2.1 Overview
    • 8.2.2 Parenteral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Gastrointestinal Drugs Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Gastrointestinal Drugs Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.1.2 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.1.3 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.1.4 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.2 United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.2.2 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.2.3 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.2.4 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.3 France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 France: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.3.2 France: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.3.3 France: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.3.4 France: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.4 Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.4.2 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.4.3 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.4.4 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.5 Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.5.2 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.5.3 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.5.4 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.6 Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.6.2 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.6.3 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.6.4 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Gastrointestinal Drugs Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Sanofi SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 GSK Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Bausch Health Companies Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 AstraZeneca Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Takeda Pharmaceutical Co Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AbbVie Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Bayer AG
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Pfizer Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Gastrointestinal Drugs Market Segmentation
  • Table 2. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 4. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 8. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 12. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 16. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 20. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 24. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. Recent Organic Growth Strategies in Gastrointestinal Drugs Market
  • Table 27. Recent Inorganic Growth Strategies in the Gastrointestinal Drugs Market
  • Table 28. Glossary of Terms, Gastrointestinal Drugs Market

List Of Figures

  • Figure 1. Europe Gastrointestinal Drugs Market Segmentation, by Country
  • Figure 2. Europe Gastrointestinal Drugs Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Gastrointestinal Drugs Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Biologics: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Antidiarrheal and Laxatives: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Acid Neutralizers: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Anti-inflammatory Drugs: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Antiemetic and Antinauseants: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Europe Gastrointestinal Drugs Market Share (%) - by Application (2023 and 2031)
  • Figure 13. Irritable Bowel Syndrome: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Inflammatory Ulcerative Colitis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Crohn's Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Gastroenteritis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Celiac Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Europe Gastrointestinal Drugs Market Share (%) - by Route of Administration (2023 and 2031)
  • Figure 20. Oral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Parenteral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Europe Gastrointestinal Drugs Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 23. Hospital Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Online Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Europe Gastrointestinal Drugs Market Breakdown, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 27. Europe Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 28. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Growth Strategies in Gastrointestinal Drugs Market